Frans Feldberg is one of the founders of the Amsterdam Center for Business Analytics research institute, which valorises knowledge in the field of big data, data science and business analytics. Data Science Alkmaar also emerged from this initiative: a knowledge and innovation center in which the local government, regional business community and science work closely together.
“In valorization, it is very important to think carefully about the exchange of values between the organizations you work with and the team of scientists. There is often a tension between the period in which science yields results, which usually involves more years, and the short period in which companies expect results, driven by their business case. That is why you as a scientist must properly define what your value is in the short, medium and long term.
For example, a company that invests in a PhD student does not want to see the result of the collaboration until after four years. We therefore, for example, organize knowledge transfer sessions during the process that are of interest to both parties. The partner receives the latest scientific insights, while we benefit from his practical experience and reflection on our research. What the value exchange in valorisation projects looks like is different in every situation. Fortunately, IXA offers tailor-made support for contract formation. “
These are exciting times for Dave Koolbergen, congenital cardiac surgeon at AMC. With his company Haermonics he hopes to bring a new technology to market for postoperative pericardial flushing. It was developed upon his observation that after heart surgery often the removal of accumulated blood and clots can be achieved by flushing the pericardial space […]
AI voor veiligheid, zorg en welbevinden Contactpersoon: Dhr. prof. dr. C.G.M. (Cees) Snoek, Universiteit van Amsterdam
AMC clinical physiologist Peter Sterk’s idea to explore the use of e-nose technology for diagnosis of lung disease has really payed off. His brand-new ‘SpiroNose’ breath analyser will shortly become available for hospitals and general practices. Sterk is confident about the clinical validation studies that are now underway: “The SpiroNose will be a formidable addition […]